Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Targeted DNA/RNA Sequencing Market Analysis, 2014 - 2025 - Research and Markets

Research and Markets
Posted on: 03 Nov 17

The "Targeted DNA/RNA Sequencing Market Analysis By Technology, By Workflow, By Application, By Type, By End-use, And Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

The global targeted DNA/RNA sequencing market is expected to reach USD 15.9 billion by 2025

Targeted Sequencing has emerged as a key technology in life science research by enabling examination of specific region of interest while keeping the seq. cost as well as complexity of data under manageable limits.

This approach enhances sequencing depth by allowing evaluation of specific coding regions within genes or specific genes, which are known to harbor mutations for disease pathogenesis. Several research projects have employed this technology to avoid wastage of information and extra cost and study only relevant genes. Number of such projects continue to grow, consequently driving the market.

Innovations to address the pitfalls of targeted enrichment method are anticipated to enhance the usage rate of this technology throughout the forecast period. Moreover, with decrease in seq-cost and improvement in informatics, targeted methods have become more accessible for use in clinical settings than ever.

Illumina, Inc.; F. Hoffmann-La Roche Ltd; QIAGEN, Thermo Fisher Scientific, Inc.; and Oxford Nanopore Technologies are some of the major companies operating in this space

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Targeted DNA/RNA Sequencing Market Variables, Trends & Scope

Chapter 4 Targeted DNA/RNA Sequencing: Technology Estimates & Trend Analysis

Chapter 5 Targeted DNA/RNA Sequencing: Workflow Estimates & Trend Analysis

Chapter 6 Targeted DNA/RNA Sequencing: Application Estimates & Trend Analysis

Chapter 7 Targeted DNA/RNA Sequencing: Type Estimates & Trend Analysis

Chapter 8 Targeted DNA/RNA Sequencing: End-use Estimates & Trend Analysis

Chapter 9 Targeted DNA/RNA Sequencing: Regional Estimates & Trend Analysis, by S Technology, Workflow, Application, Type, and End-use

Chapter 10 Competitive Landscape

  • Illumina, Inc.
  • Hoffmann-La Roche Ltd
  • Agilent Technologies
  • PierianDx
  • Genomatix GmbH
  • GATC Biotech Ag
  • Oxford Nanopore Technologies
  • Macrogen, Inc.
  • Thermo Fisher Scientific, Inc.
  • DNASTAR Inc.
  • QIAGEN
  • BGI
  • Perkin Elmer, Inc.
  • Pacific Biosciences of California, Inc.
  • Bio-Rad Laboratories, Inc.
  • Integrated DNA Technologies, Inc.
  • RainDance Technologies, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/xxtkgr/targeted_dnarna

View source version on businesswire.com: http://www.businesswire.com/news/home/20171103005402/en/

Business Wire
www.businesswire.com

Last updated on: 03/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.